SEC Form 4 · accession 0001193125-26-279703
Tempest Therapeutics, Inc. · TPST
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew Angel
Officer — CEO and President · Director · 10% Owner
Period of report
Mar 24, 2026
Accepted (ET)
Jun 23, 2026 · 4:56 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001544227
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F1,F3 | Mar 24, 2026 | P | 231,482 | $2.16 | A | 231,482 | I | By Factor Bioscience Inc. |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A Warrant (right to buy)F2,F3,F4 | $2.16 | Mar 24, 2026 | P | 231,482 | A | — | — | Common Stock | 231,482 | 231,482 | I |
| Series B Warrant (right to buy)F2,F3,F5 | $2.16 | Mar 24, 2026 | P | 231,482 | A | — | — | Common Stock | 231,482 | 231,482 | I |
Explanation of responses
- F1On March 24, 2026, Factor Biosciences Inc. ("Factor") acquired 231,482 shares of common stock, par value $0.001 per share, of Tempest Therapeutics, Inc. ("Common Stock") and warrants to purchase 462,964 shares of Common Stock (the "Warrants"), pursuant to a Securities Purchase Agreement by and between the Issuer, Factor and two institutional investors, dated as of March 20, 2026.
- F2The combined purchase price per one share of Common Stock and accompanying one warrant to purchase one share of Common Stock was $2.16.
- F3The Reporting Person is the majority stockholder and Chairman of the Board of Directors of Factor and exercises voting and investment power over the shares held by Factor.
- F4The Series A Warrants are subject to the approval of the Company's stockholders. The Series A Warrants will become exercisable on the effective date of the stockholder approval and have a term of five years from the effective date of the stockholder approval.
- F5The Series B Warrants are subject to the approval of the Company's stockholders. The Series B Warrants will become exercisable on the effective date of the stockholder approval and have a term of twenty-four months from the effective date of the stockholder approval.
Remarks
This transaction is being reported late due to an inadvertent administrative oversight.